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2Abstract
Berberine (BBR) is the main alkaloid of Coptis chinensis, which has been used as a
folk medicine to treat diabetes mellitus in Asian countries. We explored the possibility
that 5-AMP-activated protein kinase (AMPK) is involved in metabolic enhancement by
BBR in skeletal muscle, the important tissue for glucose metabolism. Isolated rat
epitrochlearis and soleus muscles were incubated in a buffer containing BBR, and
activation of AMPK and related events were examined. In response to BBR treatment, the
Thr172 phosphorylation of the catalytic  subunit of AMPK, an essential step for full
kinase activation, increased in a dose- and time-dependent manner. Ser79 phosphorylation
of acetyl CoA carboxylase, an intracellular substrate of AMPK, increased
correspondingly. Analysis of isoform-specific AMPK activity revealed that BBR
activated both the 1 and 2 isoforms of the catalytic subunit. This increase in enzyme
activity was associated with an increased rate of 3-O-methyl-D-glucose transport in the
absence of insulin and with phosphorylation of AS160, a signaling intermediary leading
to glucose transporter 4 (GLUT4) translocation. The intracellular energy status estimated
from the phosphocreatine concentration was decreased by BBR. These results suggest
that BBR acutely stimulates both AMPK1 and AMPK2 and insulin-independent
glucose transport in skeletal muscle with a reduction of the intracellular energy status.
31. Introduction
Skeletal muscle plays an important role in glucose metabolism and homeostasis in
humans. Skeletal muscle is the principal site of glucose transport and the rate-limiting
step in glucose utilization under physiological conditions [1, 2]. Similar to insulin
stimulation, exercise increases the rate of glucose transport into contracting skeletal
muscle by the translocation of glucose transporter 4 (GLUT4) to the surface membranes.
This phenomenon is considered to be responsible for the acute hypoglycemic effect of
exercise, with glucose in the blood being taken up by contracting skeletal muscles. Indeed,
the exercise-stimulated GLUT4 translocation is not impaired in insulin-resistant
conditions such as type 2 diabetes mellitus and obesity [3]. Thus, the insulin-independent
mechanisms of exercise have been widely used to decrease blood glucose in patients with
type 2 diabetes mellitus.
It has been demonstrated that exercise and insulin use different signaling
mechanisms in skeletal muscle, and 5-AMP-activated protein kinase (AMPK) has been
identified as part of the mechanisms leading to the acute enhancement of glucose
transport in contracting muscles (reviewed by Kahn et al [4], Hardie et al [5], and Fuji et
al [6]). AMPK is a member of a metabolite-sensing protein kinase family and acts as an
energy-sensing and signaling molecule in muscle cells by monitoring cellular energy
levels, such as the AMP to adenosine triphosphate (ATP) ratio. Skeletal muscle AMPK is
also implicated in a variety of antidiabetic properties of exercise, including GLUT4
expression [7, 8], glycogen regulation [9, 10], fatty acid oxidation [11, 12], mitochondrial
biogenesis [13, 14], and enhanced insulin sensitivity [8, 15, 16]. In addition, skeletal
muscle AMPK mediates part of the action of adipokines, including leptin and adiponectin,
4in glucose and lipid homeostasis, and the antidiabetic effect of metformin (MET)
(reviewed by Kahn et al [4] and Hardie et al [5]). Thus, through these effects in skeletal
muscle AMPK serves as a metabolic activator that may reduce the risk for type 2 diabetes
mellitus.
Recent reports show that berberine (BBR), a natural plant alkaloid, stimulates
glucose transport and activates AMPK in L6 cultured myocytes [17, 18]. BBR decreases
intracellular energy status, represented by the AMP/ATP ratio [17]; and it has been
suggested that BBR and its more biologically available derivative dihydroberberine
inhibit cellular respiration by inhibiting complex 1 of the mitochondrial respiratory chain
in L6 myotubes [19]. BBR is isolated from medicinal plants, such as Coptis chinensis
(family Ranunculaceae), a Chinese herb that has been used for thousands of years in Asia
to treat diabetes; and BBR treatment has beneficial effects on hyperglycemia in patients
with type 2 diabetes mellitus [20, 21]. Considering that BBR and exercise can exert
similar effects in stimulating AMPK accompanied with energy deprivation, skeletal
muscle might be the principal site of action for the antidiabetic effect of BBR. However,
to our knowledge no study has examined the direct effects of BBR on AMPK activity in
skeletal muscle tissue. AMPK is a heterotrimeric kinase, consisting of a catalytic
-subunit and two regulatory subunits,  and . Two distinct -isoforms (AMPK1 and
2) exist in skeletal muscle. It is notable that AMPK1 is the predominant -isoform and
AMPK2 activity is undetectable in L6 cells [22].
The purpose of this study was to elucidate whether BBR acts on skeletal muscle to
stimulate AMPK1 and 2 and leads to metabolic enhancement, including glucose
transport. We examined the short-term effects of BBR on both fast-glycolytic
epitrochlearis and slow-oxidative soleus muscles using an isolated rat skeletal muscle
5preparation.
62. Materials and Methods
2.1. Experimental animals and materials
Male Wistar rats aged 5 weeks and weighing 100 to 120 g were obtained from
Shimizu Breeding Laboratories (Kyoto, Japan). The animals were housed in an animal
room maintained at 23 C with a 12:12 hour light/dark cycle and fed a standard laboratory
diet and water ad libitum. All protocols for animal use and euthanasia were reviewed and
approved by the Kyoto University Graduate School of Human and Environmental Studies
and Kyoto University Radioisotope Research Center in Japan. The rats were randomly
assigned to the experimental groups. BBR chloride was purchased from Sigma (Saint
Louis, MO).
2.2. Muscle incubation
Two muscles, epitrochlearis and soleus, were used owing to their specific fiber type
composition. The epitrochlearis is composed predominantly of fast-twitch glycolytic
fibers (60–65% fast-twitch white, 20% fast-twitch red, 15% slow-twitch red) [23], and
the soleus is composed primarily of slow-twitch oxidative fibers (0% fast-twitch white,
13% fast-twitch red, 87% slow-twitch red) [24]. Muscles were treated as described
previously [25, 26] with modifications. The rats were sacrificed by cervical dislocation
without anesthesia, and the muscles were rapidly and gently removed. Both ends of each
muscle were tied with sutures, and the muscle was mounted on an incubation apparatus
with the resting tension set to 0.5 g. To recover from AMPK activation induced during the
isolating procedure, the muscles were preincubated in 7 mL of Krebs–Ringer bicarbonate
buffer (KRB): 117 mmol/L NaCl, 4.7 mmol/L KCl, 2.5 mmol/L CaCl2, 1.2 mmol/L
7KH2PO4, 1.2 mmol/L MgSO4, and 24.6 mmol/L NaHCO3 containing 2 mmol/L of
pyruvate (KRBP) for 30 minutes.
The muscle was then incubated in 7 mL of fresh buffer containing various
concentrations (0–0.6 mmol/L) of BBR for 30 minutes. The muscles were also incubated
with 2 mmol/L of 5-aminoimidazole-4-carboxamide-1--D-ribonucleoside (AICAR) for
30 minutes, 0.5 mmol/L 2,4-dinitrophenol (DNP) for 15 minutes or 1 mol/L insulin for
30 minutes to elicit maximal activation of AMPK (AICAR, DNP) or glucose transport
(insulin) in isolated rat muscle [25, 27]. The muscles were also incubated with 2 mmol/L
MET for 30 minutes [28]. To measure the time course of changes in AMPK
phosphorylation, the muscles were preincubated for 30 minutes, and then incubated in the
presence of BBR (0.3 mmol/L) for 0, 15, 30, 45 or 60 minutes. The buffer was bubbled
with gas continuously using a mixture of 95% O2–5% CO2 and maintained at 37 C. The
muscle was then either used fresh to measure glucose uptake (see 3-O-methyl-D-glucose
(3MG) transport) or frozen immediately in liquid nitrogen for the subsequent
measurement of isoform-specific AMPK activity, adenosine triphosphate (ATP) and
phosphocreatine (PCr) concentrations, and western blot analysis.
2.3. Western blot analysis
Sample preparation and western blot analysis for detection of phosphorylated
AMPK, total AMPK and phosphorylated acetyl CoA carboxylase (ACC) were
performed as described previously [26]. The muscle was homogenized in ice-cold lysis
buffer (1:40 wt/vol) containing 20 mmol/L Tris–HCl (pH 7.4), 1% Triton X, 50 mmol/L
NaCl, 250 mmol/L sucrose, 50 mmol/L NaF, 5 mmol/L sodium pyrophosphate, 2 mmol/L
dithiothreitol, 4mg/L leupeptin, 50 mg/L trypsin inhibitor, 0.1 mmol/L benzamidine, and
80.5 mmol/L phenylmethylsulfonyl fluoride (Buffer A), and centrifuged at 16,060  g for
30 minutes at 4 C. The supernatant (10 g of protein) was mixed with Laemmli’s sample
buffer containing mercaptoethanol and boiled, and the denatured proteins were separated
on either a 10% polyacrylamide gel for AMPK and Akt, or a 6% gel for ACC.
The muscle for western blot analysis of phosphorylated p38 mitogen-activated
protein kinase (MAPK) and phosphorylated p44/42 MAPK was homogenized in ice-cold
lysis buffer (1:40 wt/vol) containing 20 mmol/L HEPES (pH 7.4) , 1.5% Triton X-100, 50
mmol/L NaF, 5 mmol/L Na4P2O7, 50 mmol/L -glycerophosphate (disodium-5-hydrate),
250 mmol/L sucrose, 5 mmol/L EDTA-Na and EGTA-Na, 50 mg/L soybean trypsin
inhibitor, 2 mmol/L dithiothreitol, 4mg/L leupeptin, 25 mg/L aprotinin, 0.1 mmol/L
benzamidine, 1 mmol/L Na3VO4, and 0.5 mmol/L phenylmethylsulfonyl fluoride, and
centrifuged at 16,060  g for 30 minutes at 4 C. The supernatant (10 g of protein) was
mixed with the loading buffer containing mercaptoethanol and boiled, and the denatured
proteins were separated on a 10% polyacrylamide gel.
The proteins were then transferred to polyvinylidene difluoride membranes at 100 V
for 1 h. The membrane was blocked overnight at 4 C with Block Ace (Yukijirushi
Nyugyo, Tokyo, Japan) and then incubated with AMPK (#2532; Cell Signaling
Technology, Beverly, MA), phosphospecific AMPK Thr172 (#2531; Cell Signaling
Technology), phosphospecific ACC Ser79 (#07-303; Upstate Biotechnology, Lake Placid,
NY), phosphospecific Akt Ser473 (#9271; Cell Signaling Technology), phospho-p38 MAP
Kinase Thr180/Tyr182 (#9211; Cell Signaling Technology) or phospho-p44/42 MAP
Kinase Thr202/Tyr204 (#9101; Cell Signaling Technology).
To immunoprecipitate the Akt substrate of the 160 kd (AS160), an aliquot of the
supernatant of Buffer A was prepared as described above (300 g of protein) and
9incubated with anti-AS160 (Rab-GAP) (# 07-741; Upstate Biotechnology) and protein
A-Sepharose CL4B beads (Amersham Biosciences, Uppsala, Sweden) overnight at 4 C
with end-over-end rotation. The immunoprecipitate was washed three times in Buffer A
and then centrifuged at 4 000g for 30 seconds at 4 C. The supernatant was removed, and
the beads were mixed with the loading buffer and boiled. The denatured proteins were
then separated on a 10% polyacrylamide gel. The proteins were then transferred to
polyvinylidene difluoride membranes at 100 V for 1 hour. The membrane was blocked
with Block Ace (Yukijirushi Nyugyo) overnight at 4 C, and then incubated with
anti-AS160 (Rab-GAP) (#30544; Upstate Biotechnology) or antiphospho-(Ser/Thr) Akt
substrate (#9611; Cell Signaling Technology) as described previously [29].
The membrane was washed, reacted with anti-rabbit IgG coupled to peroxidase, and
developed with enhanced chemiluminescence reagents according to the manufacturer’s
instructions (Amersham Biosciences, Buckinghamshire, United Kingdom). The signals
on the blot were detected and quantified using a Lumino LAS-1000 System image
analyzer (Fuji Photo Film, Tokyo, Japan). The mean intensity of basal samples in each
membrane was used as a reference for controlling gel-to-gel variation. Equal protein
loading and transfer was confirmed by Coomassie brilliant blue staining of the
membranes.
2.4. Isoform-specific AMPK activity assay
The AMPK activity assay was performed as we described previously [26, 27].
Muscle was homogenized in Buffer A as described in the western blot analysis subsection
and the resultant supernatant liquid (100 g of protein) was immunoprecipitated with
isoform-specific polyclonal antibodies directed against the 1 or 2 catalytic subunit of
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AMPK [26] and protein A-Sepharose CL4B beads. The immunoprecipitate was washed
twice in both Buffer A and wash buffer (240 mmol/L HEPES, 480 mmol/L NaCl). The
kinase reaction was performed in 40 mmol/L HEPES (pH 7.0), 0.1 mmol/L SAMS
peptide [26, 27], 0.2 mmol/L AMP, 80 mmol/L NaCl, 0.8 mmol/L dithiothreitol, 5
mmol/L MgCl2, 0.2 mmol/L ATP (2 Ci of [-32P] ATP (PerkinElmer, Wellesley, MA), in
a final volume of 40 L for 20 minutes at 30 C. At the end of the reaction, a 15 L aliquot
was removed and spotted onto Whatman P81 paper (Whatman International, Maidstone,
United Kingdom). The filter paper was washed at least six times in 1% phosphoric acid
and once in acetone. 32P incorporation was quantified using a scintillation counter, and
kinase activity was expressed as picomoles of incorporated ATP per milligram of
immunoprecipitated protein per minute.
2.5. ATP and PCr assay
ATP and PCr content were measured fluorometrically in perchloric acid extracts of
epitrochlearis and soleus muscles according to the method of Lowry and Passonneau [30].
In brief, each frozen muscle was homogenized in 0.2 mol/L HClO4 (3:25 wt/vol) in an
ethanol-dry ice bath (–20 C to –30 C) and centrifuged at 16,000  g for 2 minutes at –9
C. The supernatant of the homogenate was neutralized with a solution of 2 mol/L KOH,
0.4 mol/L KCl and 0.4 mol/L imidazole, centrifuged at 16 000g for 2 minutes at –9 C and
then subjected to enzymatic analysis [30]. ATP and PCr content were expressed as
nanomoles per milligram wet weight of muscle.
2.6. 3MG transport
The 3MG transport assay was performed as we described previously [25, 26]. The
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muscle was transferred to 2 mL of KRB containing 1 mmol/L of
3-O-[methyl-3H]-D-glucose (1.5 Ci/mL) (American Radiolabeled Chemicals, St. Louis,
MO) and 7 mmol/L D- [14C]-mannitol (0.3 Ci/mL) (American Radiolabeled Chemicals)
at 30 C and incubated for 10 minutes. The muscle was blotted onto filter paper, trimmed,
frozen in liquid nitrogen, and stored at −80 C. Each frozen muscle was weighed and
incubated in 300 L of 1 mol/L NaOH at 80 C for 10 minutes. The digest was neutralized
with 300 L of 1 mol/L HCl, and the particulates were precipitated by centrifugation at 20
000g for 2 minutes. The radioactivity in aliquots of the digested protein was measured
using liquid scintillation counting for dual labels, and the extracellular and intracellular
spaces were calculated [31].
2.7. Statistical analysis
The data are expressed as means ± S.E. The mean values were compared using a
1-way analysis of variance (ANOVA) followed by a post hoc comparison with Fisher’s
protected least-significant difference method. Two mean values were compared using
student’s t-test. Differences between the groups were considered significant if P < .05.
12
3. Results
3.1. BBR increased phosphorylation of AMPK  Thr172 in skeletal muscles
The Thr172 residue in both the 1 and 2 catalytic subunits is the primary site
responsible for AMPK activation. To determine whether BBR activates AMPK, we
measured the degree of phosphorylation of AMPK Thr172 using western blot analysis
employing a phosphospecific antibody. Compared with the basal condition, both
epitrochlearis (Fig. 1A) and soleus (Fig. 1B) muscles stimulated with BBR (0.3 mmol/L,
30 minutes) exhibited increased phosphorylation of Thr172 without any change in the total
amount of AMPK. ACC is a downstream target of AMPK in skeletal muscle, and the
phosphorylation of the Ser79 site of ACC reflects the total AMPK activity [32, 33]. The
marked phosphorylation of ACC paralleled the increase in AMPK phosphorylation in
epitrochlearis (Fig. 1A) and soleus (Fig. 1B) muscles. The AMPK activator AICAR also
caused a strong phosphorylation of AMPK and ACC in epitrochlearis (Fig. 1A), but not
in soleus (Fig.1B). AICAR is taken up into skeletal muscle and metabolized by adenosine
kinase to form ZMP, a monophosphorylated derivative that mimics the effects of AMP on
AMPK [5]. The pharmacological inhibitor of oxidative phosphorylation, DNP, which
induces a marked reduction of muscle ATP and PCr levels [27], also caused significant
phosphorylation of AMPK and ACC in both muscle types (Figs. 1A and B). Metformin
elicited moderate phosphorylation of AMPK and ACC in both muscles (Figs. 1A and B).
To determine the dose and time dependency of the AMPK phosphorylation, muscles
were stimulated with BBR at various concentrations and for various times. The
dose-response study showed a significant phosphorylation of 1.2-, 1.6- and 2.0-fold in
epitrochlearis muscle (Fig. 2A), and 1.6-, 2.7- and 2.6-fold in soleus muscle (Fig. 2B) at
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concentrations of 0.1, 0.3 and 0.6 mmol/L of BBR, respectively. The time-course study
revealed that 0.3 mmol/L of BBR induced acute phosphorylation of AMPK in both
epitrochlearis (Fig. 3A) and soleus (Fig. 3B) muscles after an incubation period as short
as 15 minutes.
3.2. BBR activated both AMPK 1 and 2 in skeletal muscles
To identify which catalytic subunit is activated by BBR, isoform-specific AMPK
activity was measured in anti-1 and anti-2 immunoprecipitates of the muscle after
treatment with BBR. BBR stimulation (0.3 mmol/L, 30 minutes) significantly increased
the activity of both AMPK1 and AMPK2 in epitrochlearis muscle, the activity of
AMPK1 = 14.0  1.1 pmol/(mg min) in the basal condition and 50.7  2.9 pmol/(mg
min) after incubation with BBR; and the activity of AMPK2 = 12.2  1.3 pmol/(mg
min) in the basal condition and 30.4  2.5 pmol/(mg min) after incubation with BBR (Fig.
4A). In soleus muscle the activity of AMPK1 was 54.3  7.8 pmol/(mg min) in the basal
condition and 104.0  5.0 pmol/(mg min) after incubation with BBR, and the activity of
AMPK2 was 17.1  1.5 pmol/(mg min) in the basal condition and 29.3  1.9 pmol/(mg
min) after incubation with BBR (Fig. 4B).
3.3. BBR stimulated glucose transport in skeletal muscles in the absence of insulin
We investigated whether the activation of AMPK in skeletal muscle by BBR is
associated with enhanced glucose transport. In the absence of insulin, incubation with
BBR (0.3 mmol/L, 30 minutes) increased the rate of 3MG transport 1.7-fold in
epitrochlearis muscle (Fig. 5A) and 1.4-fold in soleus muscle (Fig. 5B) compared with
the basal conditions. AICAR significantly increased 3MG transport activity in
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epitrochlearis muscle (Fig. 5A), but not in soleus (Fig. 5B). Akt is a key molecule in the
insulin-stimulated signaling pathway leading to enhanced glucose transport and
metabolism. Recent studies suggest that AS160 is a downstream nexus for both
Akt-mediated and AMPK-mediated glucose transport in skeletal muscle [34, 35], and that
AS160 is an intracellular substrate of AMPK in skeletal muscle [35]. In our study, BBR
significantly increased phosphorylation of AS160 (Fig. 6) without changing the
phosphorylation status of Akt (Fig. 7). Additionally, BBR treatment had no effect on the
phosphorylation status of p38 or p44/42 MAPK (Fig. 7).
3.4. BBR decreased energy status in skeletal muscles.
AMPK is activated in response to energy-consuming stress, such as muscle
contraction, hypoxia, and inhibition of oxidative phosphorylation [27]. To clarify
whether BBR increases AMPK activity by energy deprivation, we measured the muscle
content of ATP and PCr. The decrease in ATP content was not statistically significant,
but PCr content after the stimulation of BBR (0.3 mmol/L, 30 minutes) was significantly
lower than that of the basal samples in both epitrochlearis and soleus muscles (Table 1).
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4. Discussion
Our data show three novel findings relating to the metabolic effect of BBR on
skeletal muscle. First, BBR had the ability to increase AMPK Thr172 phosphorylation
accompanied with both AMPK1 and 2 activities (Figs. 1-4). The increased
phosphorylation of endogenous substrate AS160 (Fig. 6) and enhanced 3MG transport
(Fig. 5) as well as ACC phosphorylation (Fig. 1) is indicative of a substantial increase in
AMPK activity in vivo. Second, these effects were observed in both fast-glycolytic
epitrochlearis and slow-oxidative soleus muscles, suggesting that the stimulatory effect
of BBR on AMPK is not specific to a particular muscle type. Third, BBR-stimulated
AMPK activation was associated with a reduction in the fuel status of skeletal muscle
(Table 1), as with contraction-stimulated AMPK activation.
We used an isolated muscle preparation incubated in vitro to eliminate systemic
confounders, such as circulatory, humoral and neuronal factors. In particular, we
considered the possibility that oral administration of BBR, which acts as an
-galactosidase inhibitor [36, 37], could evoke indirect metabolic changes in skeletal
muscle by suppressing glucose absorption in intestines. In addition, because AMPK1 is
activated immediately as a post mortem artifact during the dissection procedure [38], we
exposed muscles to BBR after a preincubation period sufficient to stabilize AMPK1
activity. Thus, our method made it possible to evaluate the direct effect of BBR on muscle
tissue and both AMPK1 and AMPK2 activities.
Incubation of epitrochlearis and soleus muscles with BBR ( 0.1 mmol/L,  15
minutes) increased AMPK phosphorylation in dose- and time-dependent manners, with
peak levels of phosphorylation at  0.3 mmol/L and  30 minutes (Figs. 2 and 3). We have
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recently reported that incubation of rat epitrochlearis and soleus muscles with caffeine (
3 mmol/L,  15 minutes) increases AMPK phosphorylation in dose- and time-dependent
manners [39]. We have also shown that activation of AMPKα1 and α2 by caffeine is 
associated with a reduction in phosphocreatine content and an increased rate of 3MG
transport in the absence of insulin [39]. These results suggest that BBR has similar
actions to caffeine, by acutely stimulating both AMPKα isoforms and 
insulin-independent glucose transport with a reduction of the intracellular energy status.
It is noteworthy that consumption of beverages containing caffeine including coffee and
green tea is associated with a reduced risk of type 2 diabetes mellitus [40, 41].
We examined the effects of BBR in fast-glycolytic and slow-oxidative muscles
because activation of AMPK and its effects may vary by muscle type. In the studies using
rat skeletal muscle, repeated AICAR administration elicited the greatest increases in
GLUT4 and glycogen content in fast-twitch muscles [42-44]. Daily, subcutaneous
injections of AICAR for 4 weeks increased GLUT4 and glycogen content in the red and
white quadriceps, but not in the soleus muscle in rats [43]. Furthermore, AICAR exposure
stimulated glucose transport in rat white muscles, but had no effect in soleus muscle [45,
46]. We also found significant increases in AMPK phosphorylation and 3MG transport
activity by AICAR in epitrochlearis muscle, but not in soleus (Figs. 1 and 5). In contrast,
incubation with BBR markedly increased AMPK phosphorylation and 3MG transport in
both epitrochlearis and soleus muscles (Figs. 1 and 5). Considering that caffeine
stimulates AMPK activity with a reduction of the intracellular energy status in both
incubated epitrochlearis and soleus muscles [39], energy deprivation per se may be
important in activating AMPK in rat soleus. Because of the non-muscle type-specific
stimulation by BBR, we believe that most skeletal muscles respond to BBR.
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The finding that BBR increased AMPK Thr172 phosphorylation provides evidence
that BBR induces covalent modification via upstream kinases. The LKB1 complex is
constitutively active and the binding of AMP to AMPK facilitates the phosphorylation of
AMPK by the LKB1 complex [47, 48]. Thus, LKB1 is believed to be a crucial AMPK
kinase in the response to energy deprivation in skeletal muscle. In the present study,
AMPK activation was accompanied by a decrease in PCr content (Table 1), raising the
possibility that LKB1 is involved in AMPK activation by BBR.
Although we did not examine the long-term effect of BBR on muscle metabolism,
Kim et al [49] have recently shown that intraperitoneal administration of BBR once a day
for three weeks increases AMPK and ACC phosphorylation in gastrocnemius muscle of
the db/db mouse (they did not examine the acute effect of BBR). In our earlier study,
repeated activation of AMPK by intraperitoneal injection of AICAR, three times a day for
seven days, increased GLUT4 protein and insulin-stimulated 2-deoxyglucose transport
activity in mouse soleus muscle [8]. Similarly, in ZDF rats, which are characterized by a
progressive -cell dysfunction and a leptin receptor defect, AICAR treatment over a
period of eight weeks increased whole-body insulin sensitivity, which was associated
with the level of muscle GLUT4 expression [50]. These data lead us to speculate that
repeated activation of AMPK by BBR may achieve long-term metabolic benefits in
skeletal muscle and protect against the development of diabetes. In this context, further
studies are needed to clarify whether oral administration of BBR at a physiologic dose
(1.0~1.5 g daily) [20, 21] results in AMPK activation in human skeletal muscle.
Cheng et al [17] have shown that BBR stimulates glucose transport and promotes
AMPK phosphorylation and p38 MAPK phosphorylation, and that the BBR-stimulated
glucose transport is partially inhibited by an AMPK inhibitor Compound C or p38 MAPK
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inhibitor SB202190 in L6 myotubes. In contrast, Zhou et al [51] have reported that in
3T3-L1 adipocytes BBR-stimulated glucose transport is not affected by SB203580 but is
partially inhibited by PD98059, a p44/42 MAPK kinase (MEK) inhibitor that leads to
inactivation of p44/42 MAPK. In the present study, BBR stimulation (0.3 mmol/L, 30
minutes) did not induce an increase in p38 MAPK phosphorylation or p44/42 MAPK
phosphorylation although the BBR stimulation significantly increased the rate of 3MG
transport in skeletal muscles. Our data suggest that p38 and p44/42 MAPK signaling does
not play a major role in activating glucose transport in intact skeletal muscle.
In summary, we demonstrated for the first time that BBR increases both AMPK1
and 2 activities in fast- and slow-twitch skeletal muscles, and that this activation is
accompanied by insulin-independent glucose transport and a reduction of muscle energy
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Legends
Fig. 1. Berberine (BBR) increases the phosphorylation of AMPK and acetyl CoA
carboxylase (ACC) in rat skeletal muscle. Isolated epitrochlearis (A) and soleus (B)
muscles were incubated in the absence (basal), or presence of BBR (0.3 mmol/L),
AICAR (2 mmol/L) or metformin (MET) (2 mmol/L) for 30 minutes, or in the presence
of 2,4-dinitrophenol (DNP) (0.5 mmol/L) for 15 minutes. The tissue lysate was subjected
to Western blot analysis with antibodies to phosphorylated AMPK, AMPK,
phosphorylated ACC or ACC. Representative immunoblots are shown.
Fig. 2. BBR increases phosphorylation of AMPK in a dose-dependent manner in rat
skeletal muscles. Isolated epitrochlearis (A) and soleus (B) muscles were incubated in the
presence of 0 (basal), 0.1, 0.3 or 0.6 mmol/L of BBR for 30 minutes. The tissue lysate was
subjected to Western blot analysis with antibodies to phosphorylated AMPK or
AMPK. Fold increases are expressed relative to the level in muscles of the basal group.
The values are means ± S.E. The number of muscles in each group is as follows: basal (8),
BBR 0.1 mmol/L (6), BBR 0.3 mmol/L (8), BBR 0.6 mmol/L (6). *P < .05 and **P < .01
vs. basal; #P < .05 and ##P < .01 vs. BBR 0.1 mmol/L.
Fig. 3. BBR increases phosphorylation of AMPK in a time-dependent manner in rat
skeletal muscles. Isolated epitrochlearis (A) and soleus (B) muscles were incubated in the
presence of BBR (0.3 mmol/L) for 0 (basal), 15, 30, 45 or 60 minutes. The tissue lysate
was subjected to Western blot analysis with antibodies to phosphorylated AMPK or
AMPK. Fold increases are expressed relative to the level in muscles of the basal group.
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The values are means ± S.E. The number of muscles in each group is as follows: basal (8),
BBR 15 minutes (6), BBR 30 minutes (8), BBR 45 minutes (6), BBR 60 minutes (6). *P
< .05 and **P < .01 vs. basal; #P < .05 and ##P < .01 vs. BBR 15 minutes.
Fig. 4. BBR activates both AMPK1 and 2 activities in rat skeletal muscles. Isolated
epitrochlearis (A) and soleus (B) muscles were incubated in the absence (basal) or
presence of BBR (0.3 mmol/L) for 30 minutes, or in the presence of DNP (0.5 mmol/L)
for 15 minutes. The isoform-specific AMPK activity was determined in the
anti-AMPK1 and anti-AMPK2 immunoprecipitates. Fold increases are expressed
relative to the level in muscles of the basal group. The values are means ± S.E. The
number of muscles in each group is as follows: basal (7), BBR (7), DNP (4). **P < .01 vs.
basal.
Fig. 5. BBR increases 3MG transport in rat skeletal muscles. Isolated epitrochlearis (A)
and soleus (B) muscles were incubated in the absence (basal), or presence of BBR (0.3
mmol/L), AICAR (2 mmol/L) or insulin (1 mol/L) for 30 minutes, and then 3MG
transport activity was determined. The values are means ± S.E. The number of muscles in
each group is as follows: basal (7), BBR (7), AICAR (4), Insulin (4). **P < .01 vs. basal.
Fig. 6. BBR increases phosphorylation of AS160 in rat skeletal muscles. Isolated
epitrochlearis (A) muscle was incubated in the absence (basal), or presence of BBR (0.3
mmol/L) or AICAR (2 mmol/L) for 30 minutes. Isolated soleus (B) muscle was incubated
in the absence (basal), or presence of BBR (0.3 mmol/L) for 30 minutes or DNP (0.5
mmol/L) for 15 minutes. The immunoprecipitate with anti-AS160 (Rab-GAP) was
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subjected to Western blot analysis with antiphospho-(Ser/Thr) Akt substrate or
anti-AS160 (Rab-GAP). Representative immunoblots are shown.
Fig. 7. BBR does not increase phosphorylation of Akt, p38 MAPK or p42/44 MAPK in
rat skeletal muscles. Isolated epitrochlearis (A) and soleus (B) muscles were incubated in
the absence (basal) or presence of BBR (0.3 mmol/L) for 30 minutes. The tissue lysate
was subjected to Western blot analysis with antibodies to phosphorylated Akt, p38
MAPK or p44/42 MAPK. Representative immunoblots are shown.
Table 1
BBR decreases phosphocreatine (PCr) levels in rat skeletal muscles.
Basal BBR
epitrochlearis ATP 5.7±0.5 5.2±0.4
PCr 19.7±0.7 12.9±1.6*
soleus ATP 2.5±0.3 2.1±0.3
PCr 9.8±1.2 5.5±0.5*
Isolated epitrochlearis and soleus muscles were incubated in the absence (basal) or
presence of BBR (0.3 mmol/L) for 30 minutes, and the intracellular ATP and PCr contents
(in nmol/mg wet weight of muscle) were measured. The values are means ± S.E. The
number of muscles in each group is as follows: epitrochlearis; ATP (8), PCr (8), soleus;
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